Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Significant Decline in Short Interest

Posted by ABMN Staff on Jun 15th, 2025

Aytu BioPharma, Inc. (NASDAQ:AYTU – Get Free Report) was the target of a significant drop in short interest during the month of May. As of May 31st, there was short interest totalling 416,700 shares, a drop of 43.7% from the May 15th total of 740,400 shares. Based on an average daily volume of 1,320,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 7.0% of the company’s shares are short sold.

Hedge Funds Weigh In On Aytu BioPharma

A hedge fund recently raised its stake in Aytu BioPharma stock. Stonepine Capital Management LLC increased its position in shares of Aytu BioPharma, Inc. (NASDAQ:AYTU – Free Report) by 13.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 463,721 shares of the company’s stock after buying an additional 56,172 shares during the period. Stonepine Capital Management LLC owned about 7.52% of Aytu BioPharma worth $556,000 at the end of the most recent quarter. Institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Price Performance

NASDAQ:AYTU opened at $1.95 on Friday. Aytu BioPharma has a twelve month low of $0.95 and a twelve month high of $2.99. The company has a market cap of $12.03 million, a price-to-earnings ratio of -1.34 and a beta of 0.05. The stock has a fifty day simple moving average of $1.49 and a 200-day simple moving average of $1.47. The company has a current ratio of 0.98, a quick ratio of 0.81 and a debt-to-equity ratio of 0.32.

Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of ($0.17) by $0.37. The firm had revenue of $18.45 million for the quarter, compared to analyst estimates of $13.74 million. Aytu BioPharma had a negative return on equity of 19.30% and a negative net margin of 7.62%.

About Aytu BioPharma

(Get Free Report)

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.